Clinical Trial

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
Protocol Amendment History 1 change
critical Trial completed 2026-07-08
Trial Details
NCT Number NCT07089706
Lead Sponsor ModernaTX, Inc.
Conditions COVID-19
Enrollment 832 participants
Start Date 2025-07-21
Primary Completion 2026-06-16 (estimated)
Study Completion 2026-06-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-07